39 results on '"G. PFISTER"'
Search Results
2. PD57-12 WHICH PATIENTS WITH OLIGOMETASTATIC PROSTATE CANCER SHOULD BE CONSIDERED FOR CYTOREDUCTIVE RADICAL PROSTATECTOMY AS PART OF A MULTIMODAL TREATMENT? RESULTS FROM A LARGE, MULTI-INSTITUTIONAL COLLABORATION
3. MP11-11 VALIDATION AND IMPLEMENTATION OF A MOBILE APP DECISION SUPPORT SYSTEM FOR QUALITY ASSURANCE OF MULTIDISCIPLINARY TUMOR BOARDS (MTD) TO OPTIMIZE MANAGEMENT OF ADVANCED TESTICULAR CANCER
4. MP79-07 VALIDATION AND IMPLEMENTATION OF A MOBILE APP DECISION SUPPORT SYSTEM FOR QUALITY ASSURANCE OF TUMOR BOARDS. ANALYZING THE CONCORDANCE RATES FOR PROSTATE CANCER AT A MULTIDISCIPLINARY TUMOR BOARD OF A TERTIARY REFERRAL CENTRE
5. PD63-02 RELIABILITY OF MODERN IMAGING STUDIES FOR DETECTION AND FINAL PATHOHISTOLOGICAL STAGE IN MEN UNDERGOING RADICAL SALVAGE PROSTATECTOMY (RSP) FOR RADIORECURRENT PROSTATE CANCER (RPC)
6. PD63-11 RADICAL SALVAGE PROSTATECTOMY (RSP) FOR RADIORECURRENT PROSTATE CANCER (RPCA): ONOLOGICAL AND FUNCTIONAL OUTCOME OF A LARGE CONTEMPORARY SERIES
7. PD16-02 ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF CYTOREDUCTIVE RADICAL PROSTATECTOMY (CRP) IN MEN WITH METASTATIC HORMONE-NAIVE PROSTATE CANCER (MHNPCA)
8. MP79-16 LONG-TERM RESULTS OF CYTOREDUCTIVE RADICAL PROSTATECTOMY IN MEN WITH HORMONE-NAIVE, LOW VOLUME METASTATIC PROSTATE CANCER(MHNPCA)
9. PD16-04 RADICAL PROSTATECTOMY VERSUS RADIOTHERAPY IN M1A AND LOW VOLUME M1B PROSTATE CANCER PATIENTS: AN INDIRECT COMPARISON WITH THE STAMPEDE TRIAL ARM H
10. MP76-05 VALIDATION OF THE BEST MODELS TO PREDICT PATHOHISTOLOGY IN GERM CELL TUMOR PATIENTS UNDERGOING POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION
11. PD57-12 THE IMPACT OF PERSISTENTLY ELEVATED PSA LEVELS ON PROGRESSION AND SURVIVAL OF PATIENTS UNDERGOING CYTOREDUCTIVE RADICAL PROSTATECTOMY FOR OLIGOMETASTATIC PROSTATE CANCER
12. MP73-13 COMPREHENSIVE ANALYSIS OF METASTATIC SEMINOMA GERM CELL TUMORS SHOWS DIVERGENT EXPRESSION OF IMMUNE-RELATED PATHWAYS
13. MP22-17 BIOCHEMICHAL RECURRENCE IN PROSTATE CANCER AFTER SALVAGE SURGERY IN CORRELATION TO THE SITE OF RECCURRENT DISEASE
14. MP49-01 PREDICTORS OF THROMBOSIS IN TESTICULAR CANCER DURING PLATINUM-BASED CHEMOTHERAPY
15. PD56-03 INDEPENDENT VALIDATION OF TWO MODELS TO PREDICT NECROSIS/FIBROSIS IN POST CHEMOTHERAPY RESIDUAL RETROPERITONEAL MASSES OF PATIENTS WITH ADVANCED TESTICULAR CANCER
16. MP28-13 IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES TO PREDICT RADIORESISTANT PROSTATE CARCINOMAS
17. MP37-20 SURGICAL MANAGEMENT OF THE GROWING TERATOMA SYNDROME: A MULTICENTER STUDY
18. PD42-06 SALVAGE RADICAL PROSTATECTOMY (SRP) FOR RADIORESISTANT PROSTATE CANCER (PCA): OUTCOME ANALYSIS OF 2 TERTIARY REFERAL CENTRES
19. MP16-03 ONCOLOGICAL AND FUNCTIONAL OUTCOME OF RADICAL SALVAGE PROSTATECTOMY IN A LARGE CONTEMPORARY SERIES
20. MP68-01 EFFECTS AND OUTCOMES OF URETERAL STENTING PRIOR TO URETEROSCOPY VERSUS PRIMARY URETEROSCOPY IN URINARY STONE TREATMENT
21. MP53-20 RADIUM-223(RAD) IN MEN WITH SYMPTOMATIC CASTRATION-RESISTANT PROSTATE CANCER: GUIDELINE VERSUS CLINICAL REALITY
22. MP24-05 UPPER URINARY TRACT DECOMPRESSION USING ILEAL URETER REPLACEMENT IN COMPARISON TO ENDOURETERAL THERMOEXPANDABLE STENT [MEMOKATH 051]
23. PD53-01 NON-GUIDELINE CONCORDANT TREATMENT OF TESTICULAR CANCER
24. MP80-03 DISTRESS SCREENING IN PATIENTS WITH UROGENITAL MALIGNANCIES
25. MP79-07 LYMPH NODE STAGING IN BIOCHEMOCAL RECURRENT PROSTATE CANCER: DOES THE TRACER MATTERF-18-FLUOROETHYLCHOLINE VERSUS GA-68-PSMA-HBED-CC PET/CT
26. MP50-11 THE ROLE OF SALVAGE EXTENDED LYMPH NODE DISSECTION (LND) IN PATIENTS WITH RISING PSA AND PET/CT SCAN DETECTED NODAL RECURRENCE OF PROSTATE CANCER
27. MP61-17 CELL-FREE DNA AS A PROGNOSTIC MARKER FOR RESPONSE TO TAXAN-BASED CHEMOTHERAPY IN PROSTATE CANCER (CAP) PATIENTS
28. MP10-10 SURGICAL MANAGEMENT OF TESTICULAR CANCER PATIENTS WITH COMPLEX POSTCHEMOTHERAPY RESIDUAL MASSES: SINGLE CENTRE EXPERIENCE
29. 471 DISTINGUISHING FEATURES OF ERG ONCOPROTEIN EXPRESSION AMONG MATCHED COHORTS OF AFRICAN-AMERICAN AND CAUCASIAN-AMERICAN PROSTATE CANCER PATIENTS
30. 832 PROGNOSTIC CLINICAL PARAMETERS TO PREDICT THE NECESSITY OF RECONSTRUCTIVE VASCULAR SURGERY FOR PATIENTS WHO UNDERGO POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) FOR ADVANCED NONSEMINATOUS GERM CELL TUMORS (NSGCT). RESULTS OF THE GERMAN TESTICULAR CANCER STUDY GROUP (GTCSG) AND THE ASSOCIATION OF UROLOGIC ONCOLOGY (AUO)
31. 1478 THE ROLE OF PREVIOUS TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) ON THE ACCURACY OF NOMOGRAMS TO PREDICT FINAL PATHOLOGICAL STAGE IN MEN UNDERGOING RADICAL PROSTATECTOMY FOR PROSTATE CANCER (PCA)
32. 675 THE COMBINATION OF DOCETAXEL AND BEVAZIZUMAB AS A SECOND-LINE THERAPY IN PATIENTS WITH HRPCA AND PSA-RELAPSE
33. 673 DOCETAXEL - RECHALLENGE AT PSA RELAPSE AFTER DOCETAXEL CHEMOTHERAPY AT HORMONE REFRACTORY PROSTATE CANCER
34. 638 COMPLICATIONS OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PCRPLND) IN ADVANCED NONSEMINOMATOUS GERM CELL TUMORS – FIRST RESULTS OF THE GERMAN TESTICULAR CANCER STUDY GROUP
35. 314 GEMCITABINE BASED CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED AND METASTATIC UROTHELIAL CANCER: THE ROLE OF AGE AND COMORBIDITIES ON THERAPY CAUSED MORBIDITY AND MORTALITY
36. 1871 THE ROLE OF PREVIOUS TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) ON THE ACCURACY OF NOMOGRAMS TO PREDICT FINAL PATHOLOGICAL STAGE IN MEN UNDERGOING RADICAL PROSTATECTOMY FOR PROSTATE CANCER (PCA)
37. 186: Modified Hautmann Neobladder with a two Chimney-Type Ureteroileal Implantation Technique: Significant Decrease of Upper Urinary Tract Complications
38. 1413: Radical Retropubic Prostatectomy in Patients with High Risk Prostate Cancer
39. 588: Prediction of Residual Retroperitoneal Mass Histology following Postchemotherapy Retroperitoneal Surgery for Metastatic Nonseminomatous Germ Cell Tumors: Role of MDR-1 and Mismatch Repair Genes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.